← boardnext 2027-03-31next 2027-06
TNGX
Tango Therapeutics, Inc.distress 5/10 · elevated risk$27.56-2%today-16% from 52w high
Oncology 3
Lead: Lung Cancer · target PD-1 · est. market ~$35B (approx, global)
Revenue
pre-revenue
Liquidity
$380M
Runway
2.7 yrs
Shares 1y
+30%
Price & events
+123.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.9%
1D
-0.3%
1W
-2.9%
1M
+6.5%
3M
+135.4%
6M
+300.6%
1Y
+182.7%
2Y
+162.2%
5Y
+142.4%
All
Overview
- Market Cap
- $3.99B
- Volume
- 69.67K
- 52 Week Range
- $5.91 – $32.90
- Total Shares
- 144.65M
- Float Shares
- 69.56M
- Short %
- 26.10%
- % Held by Insiders
- 1.17%
- % Held by Institutions
- 114.38%
- RVOL
- 0.02x
- Beta
- 1.13
Pipeline stages · 4 programs
TNG456, abemaciclib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
TNG462, RMC-9805, RMC-6236
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
TNG260, PembrolizumabPD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
TNG908
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03-31 Estimated 50% readout ~2027-05-15 | Phase 1/2 | TNG456, abemaciclib | Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell Adenocarcinoma, Lung Cancer, Brain Tumor | — | recruiting |
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 1/2 | TNG462, RMC-9805, RMC-6236 | PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer | — | recruiting |
| 2026-05 | Phase 1/2 | TNG462, Pembrolizumab | Locally Advanced Solid Tumor | 225 | recruiting |
| 2026-01 | Phase 1/2 | TNG260, Pembrolizumab | Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma | 126 | recruiting |
| 2025-12-30 | Phase 1/2 | TNG908 | Locally Advanced Solid Tumor | 110 | terminated |
Catalyst news & presentations · 8
- year 2026Guided 40%conferencedata presentationsecondaryPhase 1/2vopimetostat · Initial data from combination trial with RAS(ON) inhibitorsSEC 8-K
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025readoutPhase 1/2TNG462 · Clinical data update expected in 2025SEC 8-K
- 2025readoutPhase 1/2TNG260 · Clinical data expected in 2025SEC 8-K
- 1H 2025trial initiationsecondaryPhase 1/2TNG462 · Combination trial enrollment expected to begin (with RAS inhibitors, osimertinib, pembrolizumab)SEC 8-K
- 1H 2025trial initiationsecondaryPhase 1/2TNG456 · Phase 1/2 trial enrollment expected to beginSEC 8-K
- 2024-11-06trial discontinuedTNG908 · Enrollment stopped due to lack of efficacy in glioblastoma and to prioritize TNG462SEC 8-K
- 2024-11-06partnershipTNG462 · Clinical collaboration with Revolution Medicines to evaluate TNG462 with RAS(ON) inhibitorsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $44 (+61% upside) · 12 analysts
- 2026-07-17MizuhoOutperform
- 2026-07-15JP MorganOverweight
- 2026-06-29Canaccord GenuityBuy
- 2026-06-26JefferiesHold → Buy
- 2026-06-11Canaccord GenuityBuy
- 2026-06-09Canaccord GenuityBuy
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-22How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% - Yahoo Finance Singapore
- 2026-07-20TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
- 2026-07-17TNGX Maintained by Mizuho -- Price Target Raised to $40.00 - GuruFocus
- 2026-07-17Mizuho raises Tango Therapeutics stock price target on combo data - Investing.com
- 2026-07-15Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues - Yahoo Finance
- 2026-07-15JPMorgan initiates Tango Therapeutics stock at Overweight - Investing.com
- 2026-07-09Does Tango Therapeutics' (TNGX) Russell Growth Shift Reveal Its True Biotech Identity to Institutions? - simplywall.st
- 2026-07-02Tango Therapeutics Rides a New Precision Oncology Trend in 2026 - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.